04.09.2017 | DFP-Fortbildung | Ausgabe 1-4/2017
Mammakarzinom
- Zeitschrift:
- Wiener klinische Wochenschrift Education > Ausgabe 1-4/2017
Tipp
Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Anzeige
1.
Zurück zum Zitat IARC. Breast cancer: Estimated incidence, mortality & prevalence. 2012. http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2. Zugegriffen: 15.08.2017 IARC. Breast cancer: Estimated incidence, mortality & prevalence. 2012.
http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2. Zugegriffen: 15.08.2017
2.
Zurück zum Zitat Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005. CrossRefPubMed Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005.
CrossRefPubMed
3.
Zurück zum Zitat Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30. CrossRefPubMedPubMedCentral Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.
CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86. CrossRefPubMed Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.
CrossRefPubMed
5.
Zurück zum Zitat Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344(4):276–85. CrossRefPubMed Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344(4):276–85.
CrossRefPubMed
6.
Zurück zum Zitat Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–34. https://doi.org/10.1016/S0140-6736(13)60140-3. CrossRefPubMedPubMedCentral Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–34.
https://doi.org/10.1016/S0140-6736(13)60140-3.
CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009. CrossRefPubMed van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.
CrossRefPubMed
8.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47. CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.
CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Onkologie AG. Empfehlungen gynäkologische Onkologie Kommission Mamma 2017. 2016. http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/. Onkologie AG. Empfehlungen gynäkologische Onkologie Kommission Mamma 2017. 2016.
http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/.
10.
Zurück zum Zitat Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305. CrossRefPubMedPubMedCentral Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.
CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. CrossRef Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
CrossRef
12.
Zurück zum Zitat Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144–9. CrossRefPubMed Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144–9.
CrossRefPubMed
13.
Zurück zum Zitat Cuzick J. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast. 2003;12(S1):47. CrossRef Cuzick J. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast. 2003;12(S1):47.
CrossRef
14.
Zurück zum Zitat Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18. CrossRefPubMedPubMedCentral Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.
CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative G.. Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001; https://doi.org/10.1002/14651858.CD000486. Early Breast Cancer Trialists’ Collaborative G.. Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001;
https://doi.org/10.1002/14651858.CD000486.
16.
Zurück zum Zitat Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19. CrossRefPubMed Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19.
CrossRefPubMed
17.
Zurück zum Zitat Lange CA, Yee D. Endocr Relat Cancer 2011;18:C19–24. http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2 CrossRefPubMedPubMedCentral Lange CA, Yee D. Endocr Relat Cancer 2011;18:C19–24.
http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2
CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. CrossRefPubMed Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.
CrossRefPubMed
19.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44. CrossRef Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.
CrossRef
20.
Zurück zum Zitat Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B‑31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc Am Soc Clin Oncol. 2007;25(18 suppl):512. Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B‑31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc Am Soc Clin Oncol. 2007;25(18 suppl):512.
21.
Zurück zum Zitat Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. CrossRefPubMed Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.
CrossRefPubMed
22.
Zurück zum Zitat Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012; https://doi.org/10.1155/2012/417673. PubMedPubMedCentral Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012;
https://doi.org/10.1155/2012/417673.
PubMedPubMedCentral
- Titel
- Mammakarzinom
- Autor:
-
Kathrin Strasser-Weippl
- Publikationsdatum
- 04.09.2017
- DOI
- https://doi.org/10.1007/s11812-017-0086-4
- Verlag
- Springer Vienna
- Zeitschrift
-
Wiener klinische Wochenschrift Education
Ausgabe 1-4/2017
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765